Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Now that Zogenix's FINTEPLA is approved by the FDA, how does the label impact the commercial prospects of the drug?

Ticker(s): ZGNX, GWPH

Who's the expert?

A neurologist who treats pediatric epilepsy and Dravet syndrome. Ideally the doctor will have experience with fenfluramine, or at close knowledge of the label and landscape.

Interview Goal

With the approval of Fintepla on 6/25/20 the FDA label is known. This conversation will discuss the black box warning, the cardiac monitoring and commercial prospects of the drug for patients with Dravet.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.